Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1092 | Evodiamine |
| Evodiamine, a novel non-pungent vanilloid receptor agonist, which has the effects of anti-obese, analgesic, vasodilator, anti-oxidation, anti-inflammatory and anti-cancer. It prevents the accumulation of perivisceral fat and the body weight increase, blocks of the Ca2+ influx through receptor-mediated Ca2+ channels, inhibits NF-kB activation through suppression of IkB kinase activity. | |
| BCN1095 | Peiminine |
| Peiminine has potent anti-inflammatory, anti-allergic, antitussive, and expectorant effects. It induces autophagic cell death thus represses colorectal carcinoma tumor growth. Peiminine can inhibit lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury, by reducing circulating IFN-γ levels and inhibiting signal transduction pathways involving TGF-β, CTGF, ERK1/2, NF-κB and FasL. | |
| BCN1104 | Epifriedelanol |
| Epifriedelanol has antitumor activity, it can reduce cellular senescence in human primary cells and may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases. Epifriedelanol exhibits significant inhibition of NF-kappa B, it may be used to treat asthma. | |
| BCN1108 | 2-Hydroxy-3-methylanthraquinone |
| 1. 2-Hydroxy-3-methylanthraquinone enhances apoptosis of U937 cells,in part,through activation of p-p38MAPK and downregulation of p-ERK1/2; triggers caspase-3 activation mediated apoptotic induction. 2. 2-Hydroxy-3-methylanthraquinone enhances apoptosis of THP-1 cells, in part, through activation of Fas/FasL, DR4 and TRAIL; triggers caspase-8 activation mediated apoptotic induction. | |
| BCN1112 | Rhoifolin |
| Rhoifolin possesses a variety of significant biological activities including antioxidant, anti-inflammatory, antimicrobial, hepatoprotective and anticancer effects, it may be beneficial for diabetic complications through its enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and GLUT4 translocation. Rhoifolin has a radioprotective effect against radiation-induced decrease of blood platelets and cardiac biochemical lesions in whole body irradiated mice. | |
